CMS opens the second CY 2027 Medicare Plan Finder benefit and drug-pricing preview through September 11
Oct 4, 2026 edition · GC-2026-0083 · Published 2026-10-04 · Version 2 · Final
The September 8–11 benefit and drug-pricing preview has closed; its documented display limits and corrections remain relevant to unresolved plan-specific discrepancies.
What happened
CMS's September 1, 2026 memo set the second CY 2027 Medicare Plan Finder benefit and drug-pricing preview for September 8 at 6 a.m. through September 11 at 11:59 p.m., Eastern. That one-time window had ended by this October 4 edition. The memo reported no known issues and listed resolved display problems including D-SNP Part A cost-sharing, prior-authorization/referral labels and drug-tier displays. Those statements concerned the memo's preview status; they do not prove that every plan reviewed its own data or that every organization-specific discrepancy was resolved.
CMS encouraged comparison with HPMS benefit reports, noting that changes submitted after the preview's data-as-of date would not appear. The preview used 2026 Medicare-defined rates because 2027 rates were not yet released at the memo date. Drug pricing depended on submitted formulary, excluded-drug and pricing files; it showed each benefit phase without applying that phase's threshold, and could show full cash price for an unavailable location or supply frequency. CMS recommended representative comments for widespread issues rather than every instance. These limits explain why a preview result needs comparison with the underlying submission and cannot be read as a final beneficiary cost quote.
Scope and timing
- Authority status
- Final
- Applicability
- Directly applicable
- Audience
- Health systems, Provider networks
- Jurisdiction
- Federal
- Affected functions
- Managed Care, Finance, IT, Compliance
- Responsible owner
- Managed Care
- Recorded date
- 2026-09-11
- Date type
- implementation
Why it matters
Documented preview limits help distinguish data defects from expected displays. Closing the milestone does not certify an organization’s review or annual enrollment readiness.
Recommended action
Verify that the September preview checks and exceptions were documented. Follow up unresolved plan-specific benefit or pricing discrepancies through the appropriate CMS support route and preserve the underlying submission comparisons.
Implementation playbook
- Compare each CY 2027 plan-benefit preview with its HPMS benefit report and record exceptions, including D-SNP Part A cost sharing and prior-authorization or referral displays. Managed Care · Due 2026-09-10
- Compare drug-pricing preview results with submitted formulary, excluded-drug and drug-pricing files, then submit representative CMS comments for each distinct defect before the preview closes at 11:59 p.m. Eastern. Managed Care · Due 2026-09-11
Sources
- CMS HPMS Memos for WK 1 September 1-4, 2026 bundleOfficial · Centers for Medicare & Medicaid Services · 2026-09-04 · Source review 2026-09-10
- CMS HPMS Memos for WK 1 September 1-4, 2026 archive pageOfficial · Centers for Medicare & Medicaid Services · 2026-09-04 · Source review 2026-09-10
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Medicare & Medicaid report →